ClearDox Recognized as it Lands on the Prestigious Chartis Research Energy50 Rankings
ClearDox delivers intelligence for commodity trading operations so they can reduce risk, keep up with demand, reduce costs, and take on new challenges and business opportunities. The ClearDox Commodity Intelligence platform, powered by AI, turns piles of paperwork and digital mayhem into clean, structured, organized data.
Powered by the ClearDox platform, the ClearDox Intelligent Applications automate critical tasks throughout the commodity trading lifecycle — while continuing to shed light on operational risk. Built for the commodities industry using Generative AI and purpose-engineered to power commodity intensive workflows, its applications handle everything — from trade confirmation and finance optimization to operations intelligence, payment processing, and compliance oversight.
'We are overjoyed that ClearDox has been recognized by Chartis as they name us to this year's Chartis Energy50 award. Many of the largest players across the energy sector now use ClearDox to automate their data intensive workflows, while achieving much deeper insights into their operationally related risk. It's achievements and recognition like this that motivate the Clear team to continue our drive to transform the commodities sector with the power of AI,' said Rick Nelson, CEO, ClearDox.
The Chartis Energy50 is compiled by Chartis Research, a renowned authority in the global risk technology market. Chartis Research, a division of Infopro Digital, is dedicated to empowering enterprises with invaluable insights and analysis to enhance risk management, corporate governance, and compliance efforts. As a trusted source of in-depth assessments and actionable recommendations, Chartis Research assists organizations in making informed decisions about their technology and business strategies.
'ClearDox's application of innovative technology to a historically challenging set of processes is reflected in its top-half placing in Energy50 2025,' said Sid Dash, Chief Researcher at Chartis. 'Particularly notable is its strength in automating document related processes for energy trading and other commercial activities.'
About ClearDox LLC
ClearDox ® enables commodity organizations to reduce operationally related risk, while improving business efficiency and outcomes with clearly actionable information and insights, as it automates critical data-intensive processes. Our commodity intelligence platform is engineered to integrate seamlessly and connects workflows, information, and insights using the power of AI.
ClearDox ® enables commodity organizations to reduce operationally related risk, while improving business efficiency and outcomes with clearly actionable information and insights, as it automates critical data-intensive processes. Our commodity intelligence platform is engineered to integrate seamlessly and connects workflows, information, and insights using the power of AI.
CONTACT: Media Contact:
ClearDox Public Relations
Tel: +1.888.854.4245
KEYWORD: UNITED STATES SINGAPORE UNITED KINGDOM SOUTHEAST ASIA NORTH AMERICA ASIA PACIFIC EUROPE CONNECTICUT
SOURCE: ClearDox
Copyright Business Wire 2025.
PUB: 02/11/2025 08:02 AM/DISC: 02/11/2025 08:02 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 minutes ago
- Business Wire
PPG recognized for sustainability progress by FTSE4Good for seventh consecutive year
PITTSBURGH--(BUSINESS WIRE)--PPG (NYSE:PPG) today announced its inclusion in the FTSE4Good Index Series for the seventh consecutive year. Created by global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong sustainability practices against globally recognized standards. 'At PPG, we prioritize sustainability as a competitive advantage in our products and processes based on customer demand,' said Peter Votruba-Drzal, PPG vice president, global sustainability. 'We are focused on enabling operational excellence and reducing environmental impact both in our own operations and for our customers through sustainably advantaged innovations.' The FTSE4Good indexes are used by a variety of market participants to create and assess responsible investment funds and other products. FTSE Russell evaluations are based on performance in areas such as corporate governance, health and safety, anti-corruption and environmental impact. Businesses included in the FTSE4Good Index Series meet a variety of sustainability criteria. PPG recently reported progress against its 2030 sustainability targets, including: 41% of sales from sustainably advantaged products, such as PPG ENVIRO-PRIME® EPIC200X solution that enhances corrosion protection for automotive bodies while significantly reducing energy and material requirements. Sustainably advantaged products are identified using PPG's internal methodology that validates product attributes and their contribution towards the UN Sustainable Development Goals.* 18% reduction in greenhouse gas (GHG) emissions within the company's own operations (scope 1 and 2) against its 50% reduction target by 2030. 6% reduction in value chain (scope 3) emissions against its 30% reduction target by 2030 across purchased goods and services, customer processing of sold products and end-of-life treatment of sold products. 48% of process waste reused, recycled or recovered. 28% reduction in water intensity at priority sites in water-stressed communities. 98% of key suppliers assessed against sustainability and social responsibility criteria. In addition to the FTSE4Good Index Series, PPG has been recognized for its sustainability efforts with an EcoVadis Silver rating and an AAA rating from MSCI. PPG is also listed on Barron's 100 Most Sustainable Companies, the Corporate Knights Clean 200, Newsweek Magazine's America's Most Responsible Companies, Newsweek Magazine's World's Greenest Companies and others. To learn more about PPG's sustainability progress and 2030 targets, visit *While many PPG products have sustainable attributes in their end-use that promote longevity of customer assets, the company considers products sustainably advantaged when they contribute to improved environmental outcomes or provide relative improvements over industry benchmarks. PPG: WE PROTECT AND BEAUTIFY THE WORLD® At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for more than 140 years. Through dedication and creativity, we solve our customers' biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $15.8 billion in 2024. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit Enviro-Prime, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc. CATEGORY Sustainability
Business Wire
38 minutes ago
- Business Wire
Royal Devon NHS selects Wolters Kluwer's UpToDate Enterprise Edition CDS solution
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health announced today that the Royal Devon University Healthcare NHS Foundation Trust, an organization providing acute, community and specialist services across North Devon, Mid Devon, East Devon and Exeter, is the first NHS Trust to adopt UpToDate ® Enterprise Edition, a market-leading clinical decision support (CDS) solution. The Trust includes two acute hospitals and 17 community hospitals with over 1,100 beds. 'Deploying UpToDate Enterprise Edition is an important initiative in supporting our digital innovation strategy,' said Professor Adrian Harris, Chief Medical Officer at the Royal Devon University Healthcare NHS Foundation Trust. 'By leveraging the data, analytics and AI capabilities now available within UpToDate, we can further support medical education and optimize clinical decision-making, helping us to deliver the best possible care for all patients, and enabling our local population to stay well.' UpToDate Enterprise Edition offers harmonized content and solutions for the entire care team, empowering them to make more informed, confident, and impactful decisions. Using its AI-Enhanced Search capabilities, clinicians can now experience the efficiency of receiving highly focused verbatim answers from a market leading clinical decision solution using natural language queries—a time-saver for busy healthcare professionals. The AI-powered Analytics Dashboard offers healthcare organizations the ability to harness valuable organizational data for improved efficiency and educational opportunities. 'We are pleased to be working with The Royal Devon University Healthcare NHS Foundation Trust on the roll out of UpToDate Enterprise Edition,' said Christian Cella, Vice President, International Segment for Clinical Effectiveness at Wolters Kluwer Health. 'This is an innovative solution designed for forward thinking healthcare systems that are focused on transforming care delivery through integrated workflows that provide unparalleled content and faster time to answers.' Delivering high quality, efficient healthcare services 'Providing access to an evidence-based CDS like UpToDate helps reduce variability in care, drive better patient outcomes and save clinician time through faster decision-making at the point-of-care,' Prof. Harris continued. 'Diagnosing quickly and treating appropriately with the help of CDS means better care, better patient outcomes, and better use of invaluable healthcare resources.' Over 100 independent studies of UpToDate associate the use of the resource with clinician time savings and improvements on key hospital quality and efficiency metrics such as length of stay, medical errors, and unnecessary diagnostic testing. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
Business Wire
42 minutes ago
- Business Wire
Proximie and HistoSonics Sign U.S. Partnership to Revolutionize Treatment of Liver Tumors
BOSTON--(BUSINESS WIRE)--Proximie (the 'Company'), the leading global health technology platform digitizing operating rooms, announces a partnership with HistoSonics, the manufacturer of the Edison ® Histotripsy System 1 and novel histotripsy therapy platforms used for non-invasive treatment of liver tumors. Dividends for surgeons and clinical teams are multiple: increased productivity; access to operational best practices; medical innovation, and improved patient outcomes. The U.S.-focused partnership demonstrates the value Proximie's cloud-based operating system designed for intelligent ORs offers to medical device companies, as the Company enhances the adoption and user experience of HistoSonics' Edison System. Proximie's OR intelligence platform offers a tailored digital ecosystem which drives healthcare innovation. The platform facilitates real-time connectivity; unified data – including data capture, structure, and control capabilities; AI-enabled insight; and a context-rich video library. Within the partnership, Proximie and HistoSonics integrate the Proximie platform and the Edison System to hospitals and ambulatory surgery centers across the U.S., providing significant value for healthcare system operators, physicians, and patients. Specifically, Proximie's real-time connectivity capabilities enable HistoSonics' medical directors and physician faculty to share live expertise to surgeons using the Edison System; treating patients' liver tumors more effectively via focused ultrasound sonic beam therapy; while adding new levels of rapidity to HistoSonic's diagnostics and operations. The dividends for surgeons and clinical teams are multiple: increased productivity; access to operational best practices; medical innovation, and improved patient outcomes. Initial go-live regions for the partnership include Chicago, Colorado, Florida, Louisiana, Seattle, and Southern California. Almost 300,000 patients in the U.S. alone are diagnosed with tumors in the liver, most of which originate from organs outside the liver like the colon, rectum, and pancreas, and travel to the liver. While these metastatic tumors appear in advanced stages, even primary tumors of the liver (Hepatocellular carcinoma) have a dismal 5 year survival rate of less than 18%. With the substantial unmet clinical need from so many tumors in the liver the potential for real-time histotripsy procedural support via Proximie could prove to dramatically impact patient outcomes. Dr. Nadine Hachach-Haram, Founder and CEO of Proximie, commented: 'We are thrilled to announce our partnership with HistoSonics, driving the rollout of the cutting-edge Histotripsy System while making a tangible impact on outcomes for those suffering from liver tumors. The partnership is testament to the benefits of intelligent digital connectivity within the OR; enabled by the Proximie platform; providing value to stakeholders across the healthcare ecosystem.' Mike Blue, President & CEO of HistoSonics, said: 'Our partnership with Proximie represents our commitment to partner with world leaders in their respective domains, providing our customers with the best technology solutions possible. Proximie's ability to provide real-time virtual presence in histotripsy procedures provides opportunities for our medical team to share expertise with physicians across the world and support our customers in unprecedented ways.' The Company's partnership with HistoSonics has already yielded dividends for surgeons and patients. Notably, Dr. Kevin Burns of Providence Mission Hospital has frequently utilized the Proximie platform and the Edison Histotripsy System together, benefiting patients and enabling knowledge-sharing opportunities. Dr. Kevin Burns, Chief of Interventional Radiology at Providence Mission Hospital, said: "HistoSonics' Edison Histotripsy System has drastically improved outcomes for our patients suffering with liver tumors. The system's ability to destroy tumors via non-thermal, non-invasive, personalized therapy significantly reduces recovery times - getting patients out of hospital and back on their feet more quickly, while improving our productivity and operational efficiency. Additionally, the opportunity for clinicians to share live guidance when using the Histotripsy system, via the Proximie platform, is invaluable - ensuring physicians can be confident when performing novel histotripsy therapy for the first time; guaranteeing access to cutting-edge techniques for more patients." The announcement follows recent partnerships between Proximie and numerous global MedTech players. Notably, the Company recently announced a global partnership with Olympus Corporation – the medical technology company and market leader in innovative surgical tools and endoscopy systems; and a partnership with Distalmotion – the surgical robotics pioneer and developer of the Dexter surgical robot. To date, Proximie is deployed across five continents and is working with hundreds of healthcare systems and major medical device developers – creating a truly global impact by improving access to high-quality surgical care in both developed and developing economies. Notes to Editors About Proximie Proximie is a global health technology platform focused on digitizing operating and diagnostic rooms. Proximie's mission is to make surgery more accessible, efficient, and effective for everyone, via cutting-edge, cloud-based technology. Proximie's OR intelligence platform offers a tailored digital ecosystem which drives healthcare innovation. The platform facilitates real-time connectivity, unified data – including data capture, structure, and control capabilities, – AI-enabled insight, and a context-rich video library This provides benefits for the entire healthcare ecosystem via improved productivity, optimized workflows, accelerated training, and enhanced medical technology innovation; benefiting patient outcomes. By opening-up surgery beyond traditional operating room boundaries, Proximie is facilitating a rich, insightful data set which naturally feeds best practices into the entire healthcare ecosystem. Founded by Dr. Nadine Hachach-Haram, Proximie has now been deployed in over 800 hospitals across 50 countries in five continents. Proximie has contracts with over 40 major medical device companies – with access to 90% of operating rooms and diagnostic suites in the U.K., U.S., and EU – and been published in over 20 medical journals. Proximie is the lead author of a report on ' Patient safety in surgery – the urgent need for reform ', highlighting the challenges affecting patient safety in surgery in the NHS as well as potential solutions to improve patient safety. For more information, please visit or follow @Proximie on X and LinkedIn. About HistoSonics HistoSonics is a privately held medical device company developing non-invasive platforms and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, brain, and others. HistoSonics has offices in Ann Arbor, Michigan, and Minneapolis, Minnesota. The Edison ® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any specific disease or condition. Use of the Edison System in kidney applications is limited by federal law to investigational use. The #HOPE4KIDNEY Trial is designed to support a future expansion of the indication to include the destruction of kidney tissue/tumors. 1 HistoSonics' Edison ® Histotripsy System uses proprietary technology and advanced imaging to deliver personalized, non-invasive histotripsy treatments with precision and control. The novel mechanism of action of this proprietary technology may provide significant patient advantages, including the ability of the treatment site to recover and resorb quickly. HistoSonics' platform also provides physicians the ability to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today.
